TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21458651
Drug: Implant-assisted mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-assisted mandibular dentures
Study: 15333404
Drug: Rocuronium 10
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 10 mg/mL
Study: 15333404
Drug: Rocuronium 1
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1 mg/mL
Study: 15333404
Drug: Rocuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.5 mg/mL
Study: 10950032
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg four times daily
Study: 8470632
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg four times daily
Study: 3780291
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide 100 mg twice daily for 3 days before and 100 mg 1 hour before examination
Study: 27721231
Drug: Cold dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold dialysis solution at 35.5°C
Study: 27721231
Drug: Conventional dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dialysis solution at 37°C
Study: 22695364
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 10-20 mg·kg·d orally
Study: 2196926
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1% hydrocortisone cream and 2% miconazole cream
Study: 6101961
Drug: Pirbuterol 10
Normalized name: pirbuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 10 mg four times daily
Study: 6101961
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg four times daily
Study: 22700717
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment (LLT)
Study: 19962941
Drug: Pramipexole (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.125 to 0.75 mg/day for 6 weeks)
Study: 17377856
Drug: Direct autologous
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct autologous retransfusion of shed thoracic blood (350 ml)
Study: 17377856
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (350 ml saline)
Study: 16352934
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX)
Study: 30099811
Drug: Losartan 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 5% ointment
Study: 16036167
Drug: Ginger capsule
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger capsule
Study: 16036167
Drug: Bottle filled
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bottle filled with ginger capsules
Study: 16036167
Drug: Bottle filled
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bottle filled with placebo capsules
Study: 12203743
Drug: Further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further treatment to reduce risk
Study: 12203743
Drug: Minor variations
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor variations in treatment protocol
Study: 6803278
Drug: L-tryptophan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (5 g)
Study: 6803278
Drug: Pyridoxine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (125 mg three times daily with meals) and L-tryptophan (3 g at 10 PM)
Study: 30735922
Drug: Antipsychotic switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic switch during the 8-week acute phase
Study: 25058216
Drug: Erythropoietin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (500 IU/kg per dose)
Study: 25058216
Drug: Hemoglobin transfusion
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin transfusion threshold of 10 g/dL
Study: 25058216
Drug: Transfusion threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion threshold of 10 g/dL
Study: 19777213
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BZP
Study: 17580150
Drug: Sirolimus conversion
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus conversion treatment (RAPA)
Study: 31567567
Drug: BDG-guided empiric
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDG-guided empiric antifungal treatment
Study: 24229749
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (72 mg/d)
Study: 17688463
Drug: Oral atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atypical antipsychotic (AAP)
Study: 15507939
Drug: Single-dose parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single-dose parecoxib sodium 40 mg
Study: 15507939
Drug: Multiple-dose parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Multiple-dose parecoxib sodium 20 mg, 4 times daily
Study: 15507939
Drug: Multiple-dose parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Multiple-dose parecoxib sodium 40 mg, twice daily
Study: 31462203
Drug: Accelerated initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Accelerated initiation of renal replacement therapy
Study: 28035867
Drug: SC golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SC golimumab 50 mg (Group 2-SC)
Study: 28035867
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg (Group 2-IV)
Study: 7955822
Drug: Caffeine-containing analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing analgesic (APAP/ASA/CAF: 500 mg acetaminophen, 500 mg aspirin, 130 mg caffeine)
Study: 3211484
Drug: 1.0 mg/ml
Normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/ml mitomycin eye drops
Study: 3211484
Drug: 0.4 mg/ml
Normalized name: thymol 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/ml mitomycin eye drops
Study: 27780692
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet combined with weight-loss cognitive behavioral therapy
Study: 27780692
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet combined with weight-loss cognitive behavioral therapy
Study: 21697075
Drug: 300 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU/d from supplements
Study: 21697075
Drug: a one-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: a one-time seasonal supplement of 13,700 IU
Study: 18827019
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day dehydroepiandrosterone (DHEA)
Study: 18827019
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day dehydroepiandrosterone (DHEA)
Study: 16821176
Drug: Intense activating
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense activating group treatment (subgroup analysis)
Study: 10695822
Drug: Soy formula
Normalized name: Nursoy Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy formula daily
Study: 10695822
Drug: Therapeutic oral
Normalized name: multivitamin,therapeutic ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic oral iron treatment
Study: 3002720
Drug: Ortho Vaginal
Normalized name: Ortho-Nesic
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho Vaginal Tablets (OVT)
Study: 3002720
Drug: Emko Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emko Vaginal Tablets (EVT)
Study: 28816373
Drug: 80 mL
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mL simethicone/Pronase solution plus 10 mL lidocaine hydrochloride mucilage (SP/LHM)
Study: 28816373
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL lidocaine hydrochloride mucilage (LHM)
Study: 21174129
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) sleep intervention
Study: 18349431
Drug: Subjects randomized
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to estimate the probability of treatment success after learning their diagnosis (after group)
Study: 12823159
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine at bedtime
Study: 12022436
Drug: RRV-TV (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-TV (4 x 10(4) pfu/dose)
Study: 1927942
Drug: Early patency
Normalized name: Tests for bile duct patency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early patency (both treatments)
Study: 6129609
Drug: Combined salbutamol-dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined salbutamol-dexamethasone treatment
Study: 27587605
Drug: MCO CC
Normalized name: MCO-010
DrugBank: Sonpiretigene isteparvovec (DB17844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCO CC
Study: 18270526
Drug: Food items
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food items enriched with mineral nutrients and 1.25, 2.5, and 5.0 g per day of plant sterols during the first, second, and third 5-week periods, respectively
Study: 26228214
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN)
Study: 15974216
Drug: Colgate Winterfresh
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Winterfresh Gel (CWG)
Study: 2187665
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg, single oral dose)
Study: 29098257
Drug: Oral implantation
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral implantation
Study: 12667600
Drug: Polyphenol-rich juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich juice A (236 mg polyphenols, cyanidin glycosides)
Study: 12667600
Drug: Polyphenol-rich juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich juice B (226 mg polyphenols, epigallocatechin gallate)
Study: 8795441
Drug: gamma‐L‐glutamyl‐L‐3,4‐dihydroxyphenylalanine (gludopa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma‐L‐glutamyl‐L‐3,4‐dihydroxyphenylalanine (gludopa)
Study: 8795441
Drug: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan
Study: 6372934
Drug: Cholecystokinin (CCK)
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin (CCK) infusion (1 Ivy Dog Unit/kg over 5 min)
Study: 3714912
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) infusion
Study: 6372934
Drug: Repeat CCK
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat CCK infusion postoperatively
Study: 18519174
Drug: Risedronate (RIS),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (RIS), 35 mg once weekly
Study: 7485479
Drug: L-[3,4-3H]glutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[3,4-3H]glutamine infusion
Study: 1826739
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg IV every 4 hours for three doses
Study: 1826739
Drug: Metoclopramide 2
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 2 mg/kg IV every 2 hours for three doses, then every 3 hours for three additional doses
Study: 17425814
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (recommended induction dose of propofol)
Study: 8186380
Drug: Hyoscine N-butyl
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butyl bromide (20 mg)
Study: 8186380
Drug: Propinoxate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propinoxate (5 mg) plus diazepam
Study: 2951570
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate (1% solution)
Study: 2951570
Drug: Tetracycline (solution)
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline (solution)
Study: 20234000
Drug: Web administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Web administration of the Youth Risk Behavior Survey (YRBS)
Study: 20234000
Drug: Paper-and-pencil administration
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil administration of the Youth Risk Behavior Survey (YRBS)
Study: 18567678
Drug: mct/lct-propofol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: mct/lct-propofol with lidocaine 10 mg/ml
Study: 7719761
Drug: Methylprednisolone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (3 mg/kg in saline)
Study: 31145226
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ketorolac
Study: 27763895
Drug: Low urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low urine output target of 0.2 mL/kg/h
Study: 27763895
Drug: Standard urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard urine output target of 0.5 mL/kg/h
Study: 24565620
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group (ATG) with weekly meetings with a research assistant and mp3 physician-recorded asthma messages
Study: 19735398
Drug: Cotton blanket
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton blanket with saline injection
Study: 15161075
Drug: Rectal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal vaccination with cholera toxin B subunit
Study: 15161075
Drug: Oral vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccination with cholera toxin B subunit
Study: 11484451
Drug: Josamycin 50
Normalized name: josamycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin 50 mg.kg‐1.day‐1 b.i.d for 5 days
Study: 9656557
Drug: Single nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nightly prophylactic dose of an antibiotic
Study: 9656557
Drug: Single nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nightly prophylactic dose of an antibiotic and oxybutinin as in group II
Study: 7914462
Drug: Adjunctive bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive bilateral electroconvulsive therapy (ECT)
Study: 31475497
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fuyang-pot warming and EA
Study: 21668442
Drug: Lead time
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead time to treatment
Study: 16307711
Drug: Concurrent task
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent task of randomly generating months of the year aloud (dual-task condition)
Study: 3948545
Drug: Caffeine (7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (7.2 mg/kg)
Study: 16505224
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg for 4 months)
Study: 15291903
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (acupuncture and Chinese herbal medicine)
Study: 11815726
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) every other day
Study: 14676459
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE and 2.5 mg MPA every day
Study: 11815726
Drug: Low estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low estradiol group (<15 pg/ml)
Study: 11815726
Drug: Middle estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Middle estradiol group (>=15 and <25 pg/ml)
Study: 11815726
Drug: High estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High estradiol group (>=25 pg/ml)
Study: 9794022
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and behaviour therapy
Study: 8435693
Drug: Self-help treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help treatment programme
Study: 20608035
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lascropuncture infrared radiation and manual therapy
Study: 15225178
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg/day
Study: 15225178
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day
Study: 21735688
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol (Oesclim 50) combined with oral norethisterone 2.5 mg daily (Primolut-Nor)
Study: 21735688
Drug: Oral 2
Normalized name: SYRINGE,ORAL 20ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 2 mg 17beta-estradiol combined with oral 1 mg daily norethisterone (Kliogest)
Study: 19902046
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control Group C)
Study: 16302558
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid 15% gel
Study: 15176158
Drug: Benzoyl peroxide/clindamycin
Normalized name: BENZOYL PEROXIDE/CLINDAMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide/clindamycin gel
Study: 11753747
Drug: Conventional tricyclic
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tricyclic antidepressants
Study: 25316463
Drug: Implant-retained mandibular
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained mandibular overdentures
Study: 9926766
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment modalities
Study: 31222540
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg methylprednisolone intravenously on the induction of anaesthesia
Study: 29034453
Drug: AVP-825 (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP-825 (22 mg sumatriptan nasal powder)
Study: 25567657
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg orally for 8 days + Ondansetron 8 mg intravenously 30 min before chemotherapy
Study: 25567657
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg intravenously 30 min before chemotherapy
Study: 7611577
Drug: Control (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rectal paracetamol after operation before extubation)
Study: 2698435
Drug: roxithromycin (RXT)
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (RXT) 300 mg/day orally for an average of 9 days
Study: 2698435
Drug: antibiotic/s (ATB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic/s (ATB) based on identified microorganisms, mean duration of treatment 12 days
Study: 31675299
Drug: Cruciate-Retaining (CR)
Normalized name: Gentiana cruciata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cruciate-Retaining (CR) implant
Study: 23789453
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment including melatonin
Study: 16839346
Drug: BIBT 986
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBT 986 intravenous infusion
Study: 12637979
Drug: Granulocyte‐Colony Stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte‐Colony Stimulating Factor (G‐CSF) 5 microg/kg daily for 10 days
Study: 10636257
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily metoprolol tartrate (MT)
Study: 10636257
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily metoprolol succinate (MS)
Study: 9020417
Drug: Antihistamine (mizolastine)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (mizolastine)
Study: 9020417
Drug: Azelastine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (oral application)